Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-02-24
2010-11-02
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07825130
ABSTRACT:
A new PTEN opener or a new opener of a large conductance Ca2+-activated K+channel (Maxi-K channel) which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I):wherein R is cycloalkyl, A is lower alkylene, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, which is useful as a medicament for promotion of the survival of normal cells, brain cells, heart cells, and skin, and further for inhibiting of Gram negative sepsis and cell migration and cell invasion due to inhibition of PTEN and is further useful as a medicament for the treatment of neuronal disorders, for example, an anticonvulsant, a neuroprotecting agent, a medicament for treatment of regional cerebral edema and neurologic motor impairment, cognitive disorders, traumatic brain injury, Parkinson's disease, epilepsy, migraine, and Alzheimer's disease, etc.
REFERENCES:
patent: 4277479 (1981-07-01), Nishi et al.
patent: 6019735 (2000-02-01), Kensey et al.
patent: 6187790 (2001-02-01), Cutler
patent: 6267985 (2001-07-01), Chen et al.
patent: 6294192 (2001-09-01), Patel et al.
patent: 6322524 (2001-11-01), Kensey et al.
patent: 6322525 (2001-11-01), Kensey et al.
patent: 6451339 (2002-09-01), Patel et al.
patent: 6458804 (2002-10-01), Cutler et al.
patent: 6571608 (2003-06-01), Shin et al.
patent: 6624435 (2003-09-01), Kensey et al.
patent: 6743806 (2004-06-01), Hong
patent: 4-159224 (1992-06-01), None
patent: 7-76584 (1995-03-01), None
patent: 9-157170 (1997-06-01), None
Kim, J of Pharm and Exp Therap, 2004, vol. 308(1), pp. 97-104.
Hong, J of Pharm and Exp Therap, 2003, vol. 306(3), pp. 1182-1190.
Abstract of J Pharmacol Exp Ther. Sep. 2003; 306(3): 1182-90. Epub Jun. 13, 2003.
Abstract of J Pharmacol Exp Ther. Jan. 2004; 308(1): 97-104. Epub Oct. 20, 2003.
Abstract of Journal of Pharmacology And Experimental Therapeutics Fast Forward First published on Jun. 13, 2003; DOI: 10.1124/jpet.103.052365.
CNS Drug Reviews vol. 3. No. 4 pp. 427-437 (XIVth World Congress of Pharmacology, San Francisco, CA USA Jul. 7-12, 2002 New Drugs for the Treatment of Central Nervous System Disorders).
Finnegan Henderson Farabow Garrett & Dunner LLP
Otsuka Pharmaceutical Co. Ltd.
Seaman D. Margaret
LandOfFree
PTEN inhibitor or Maxi-K channels opener does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PTEN inhibitor or Maxi-K channels opener, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PTEN inhibitor or Maxi-K channels opener will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189641